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Medulloblastoma (MB), tumor of the cerebellum, remains a leading cause of cancer-
related mortality in childhood. We previously showed, in a mouse model of spontaneous
MB (Ptch1+/−/Tis21−/−), that a defect of the migration of cerebellar granule neuron
precursor cells (GCPs) correlates with an increased frequency of MB. This occurs
because GCPs, rather than migrating internally and differentiating, remain longer in the
proliferative area at the cerebellar surface, becoming targets of transforming insults.
Furthermore, we identified the chemokine Cxcl3 as responsible for the inward migration
of GCPs. As it is known that preneoplastic GCPs (pGCPs) can still migrate and
differentiate like normal GCPs, thus exiting the neoplastic program, in this study we
tested the hypothesis that pGCPs within a MB lesion could be induced by Cxcl3 to
migrate and differentiate. We observed that the administration of Cxcl3 for 28 days
within the cerebellum of 1-month-old Ptch1+/−/Tis21−/− mice, i.e., when MB lesions
are already formed, leads to complete disappearance of the lesions. However, a shorter
treatment with Cxcl3 (2 weeks) was ineffective, suggesting that the suppression of MB
lesions is dependent on the duration of Cxcl3 application. We verified that the treatment
with Cxcl3 causes a massive migration of pGCPs from the lesion to the internal granular
layer, where they differentiate. Thus, the induction of migration of pGCPs in MB lesions
may open new ways to treat MB that exploit the plasticity of the pGCPs, forcing their
differentiation. It remains to be tested whether this plasticity continues at advanced
stages of MB. If so, these findings would set a potential use of the chemokine Cxcl3
as therapeutic agent against MB development in human preclinical studies.
Keywords: Cxcl3, chemokines, migration, preneoplastic lesions, medulloblastoma, differentiation and
reprogramming, cerebellum development, cancer therapy
INTRODUCTION
Medulloblastoma (MB), a neuroepithelial tumor developing in the cerebellum, is the most
common pediatric brain cancer and represents about 20% of all cerebral childhood tumors (Roberts
et al., 1991; Louis et al., 2007). The current therapy of MB involves preliminary surgery, radiation,
and chemotherapy. This standard multimodality treatment allows acceptable survival rates, but
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patients suffer devastating morbidity, such as permanent
neurocognitive dysfunctions (Gottardo and Gajjar, 2008) and
secondary malignancies (Goldstein et al., 1997). Thus, new, less
toxic and more targeted, therapy options are needed.
About 30% of MBs originate from the granule neuron
precursor cells (GCPs) located in the external granular
layer (EGL) at the surface of the developing cerebellum, in
consequence of the proliferative hyperactivation of the Sonic
Hedgehog (Shh) pathway (Schüller et al., 2008; Yang et al., 2008;
Gibson et al., 2010; Northcott et al., 2012). In physiological
conditions, the GCPs intensely proliferate postnatally in the EGL
mitogenic niche, under the stimulus of Shh, and exit the cell cycle
and differentiate as a result of migrating inward to molecular
and internal granular layers (ML and IGL, respectively) (Choi
et al., 2005). Given that the prolonged mitotic activity makes
the GCPs especially susceptible to cell transformation (Wang
and Zoghbi, 2001), the rate of migration, by regulating the
duration of the period during which GCPs remain proliferating
in the EGL, can impact the incidence of MBs, as we and
others have shown (Farioli-Vecchioli et al., 2012, 2013; Haag
et al., 2012). In fact, our recent study demonstrated that a new
MB Shh-type mouse model, which lacks the MB-suppressor
gene Tis21 (Ptch1+/−/Tis21−/−), develops MBs with high
frequency in consequence of a defect of migration of the
GCPs out of the EGL (Farioli-Vecchioli et al., 2007, 2012).
This defect of migration is caused by downregulation of the
chemokine Cxcl3, whose promoter is directly activated by
Tis21 (Farioli-Vecchioli et al., 2012). We also revealed the
ability of the chemokine Cxcl3 to cell autonomously induce
the migration of the GCPs out of the EGL and, remarkably,
to reduce the area of MB lesions in cerebellar slices of the
MB Ptch1+/−/Tis21−/− mouse model (Farioli-Vecchioli et al.,
2012).
It is known that the preneoplastic GCPs (pGCPs) within
MB lesions, although they are able to generate a tumor when
transplanted, can still migrate and differentiate like normal GCPs
(Yang et al., 2008; Kessler et al., 2009). Thus, we reasoned that
if pGCPs are induced to migrate out of the lesion at the surface
of the cerebellum, they may differentiate and exit the neoplastic
program.
Therefore, the chief aim of this study was to assess the
feasibility of using in vivo the pro-migratory chemokine Cxcl3 as
an agent able to reduce the frequency of tumor lesions and, hence,
to contrast the development of MB.
MATERIALS AND METHODS
Mice
The Tis21 knockout mice were previously generated in the
C57BL/6 strain as described (Park et al., 2004), by inserting the
neomycin resistance cassette within exon II of the Tis21 gene.
Patched1 heterozygous mice (Ptch1+/−) were produced in CD1
background through deletion of exons 6 and 7 (Hahn et al.,
1998). The crossing of Ptch1+/− with Tis21−/− mice generated
Ptch1+/−/Tis21−/− double-mutant mice, which were interbred
for at least six generations to obtain an isogenic progeny.
Genotyping of Ptch1+/−/Tis21−/− mice was routinely
performed by PCR analysis, using genomic DNA from tail tips
as described (Farioli-Vecchioli et al., 2012).
Experiments were performed with either male or female
mice and all animal procedures were accomplished according
to the current European Ethical Committee guidelines (directive
2010/63/EU; authorization DM 307/2013-B of the Italian
Ministry of Health).
Brain Infusion
All mice involved in our study (n = 30) were anesthetized
(80/80/10 mg/kg tiletamine HCl/zolazepam HCl/xylazine, i.p.)
and implanted with an Alzet osmotic minipump at postnatal
day 30 (P30), as described (Liao et al., 2008). Briefly, an Alzet
30-g infusion cannula (length 1.5 mm; brain infusion kit 3;
Durect Corp., Cupertino, CA, USA) was implanted into the
subarachnoid space above the rostral, dorsal cerebellum, 4 mm
caudal to lambda at midline. The Alzet minipump (1004, which
delivers 0.11 µl/h for 4 weeks; Durect Corp.) was filled with
recombinant Cxcl3 (100 µl of a solution at 20 µg/ml; 5568-
CA-025/CF, R&D Systems, Minneapolis, MN, USA) or with the
vehicle (CSF, cerebrospinal fluid solution, as per Durect Corp.
protocol: 148 mM NaCl, 3 mM KCl, 1.4 mM CaCl2, 0.8 mM
MgCl2, 8 mM Na2HPO4, 0.2 mM NaH2PO4) and placed between
the scapulas. The cannula was secured with cyanoacrylate and the
skin was closed with sutures. An intraperitoneal injection of 0.9%
normal saline was given after surgery to prevent post-operative
dehydration. Animals were monitored post-operatively until
mobile, and they were observed daily until the end of treatment
(2 or 4 weeks). The number of mice for each experimental group
is summarized in Table 1.
Bromodeoxyuridine Treatment of Mice
The pGCPs entering S-phase were detected 1 h after an injection
of bromodeoxyuridine (BrdU) (95 mg/kg, i.p.), according to
existing protocols (Canzoniere et al., 2004; Qiu et al., 2010).
The pGCPs migrating from the lesions to the inner layers were
visualized 5 days after a single injection of BrdU (95 mg/kg, i.p.)
in P39 mice.
Immunohistochemistry
At the end of treatment, the mice were euthanized under
anesthesia by transcardiac perfusion with 4% paraformaldehyde
in PBS and the cerebella were dissected and cryoprotected
in 30% sucrose in PBS. Samples were embedded in Tissue-
Tek OCT (Sakura Finetek, Torrance, CA, USA) and free-
floating sagittal sections of 40 µm were cut serially on a rotary
microtome. To detect the BrdU incorporation, the sections were
treated with 2N HCl 45 min at 37◦C and then with 0.1 M
sodium borate buffer, pH 8.5, for 10 min. The samples were
reacted with a rat monoclonal antibody against BrdU (AbD
Serotec, Raleigh, NC, USA; MCA2060; 1:300) and a mouse
monoclonal antibody raised against NeuN (Merck Millipore,
Billerica, MA, USA; MAB377; 1:100), followed by donkey anti-
rat tetramethylrhodamine isothiocyanate (TRITC)-conjugated
and donkey anti-mouse Cy2-conjugated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA, USA; 1:200). The
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TABLE 1 | Frequency of medulloblastoma lesions after Cxcl3 treatment.
Treatment Mice with MB lesions (%, #) Number of MB lesions per cerebellum∗
(Mean± SEM)
28 days in 1-month-old Ptch1+/−/Tis21−/− mice CSF Cxcl3 CSF Cxcl3
62.5 (5/8) 0.00 (0/8) 0.62 ± 0.1 0.0 ± 0.0
n (mice) analyzed 8 8 8 8
Probability (p) 0.007 (Chi square test) 0.0042 (Student’s t-test)
14 days in 1-month-old Ptch1+/−/Tis21−/− mice CSF Cxcl3 CSF Cxcl3
42.8 (3/7) 28.5 (2/7) 0.42 ± 0.2 0.28 ± 0.1
n (mice) analyzed 7 7 7 7
Probability (p) 0.57 (Chi square test) 0.61 (Student’s t-test)
∗Average number in lesioned and non-lesioned mice.
samples were then counter-stained by Hoechst 33258 (Sigma-
Aldrich, St. Louis, MO, USA; 1 mg/ml in PBS) to visualize the
ML and IGL.
Photomicrographs of the immunostained sections were
generated by Laser Scanning Confocal Microscopy with a TCS
SP5 microscope (Leica Microsystems) and analyzed by the I.A.S.
software (Delta Sistemi, Rome, Italy).
Lesion Quantification and Cell Migration
Assay
All cerebella were stained for BrdU incorporation using
fluorescent methods, as described above, to identify the presence
of lesions. For each cerebellum were examined 12 sections spaced
with intervals of 400 µm, in order to allow a representative
sampling.
The pGCPs migrating from the lesions were identified as
BrdU-labeled cells in MB lesion and neighboring layers (i.e.,
ML and IGL) and were counted as percentage ratio to the total
number of BrdU+ cells in the lesion and layers, in 10 adjacent
sagittal sections per lesion. We examined all lesions present
in each 6-week-old mouse analyzed, whose number for each
treatment is indicated in Table 1.
Statistical Analysis
The Chi square test was used to compare the percentage of
positivity for MB lesions in CSF-treated mice versus Cxcl3-
treated mice. Data of migration and differentiation of pGCPs
were calculated as the mean ± the standard error of the mean
(SEM) and compared by the Student’s t-test. All statistical tests
were two-sided and a value of p< 0.05 was considered statistically
significant.
RESULTS
The chemokine Cxcl3 or the vehicle (CSF) was administered
by Alzet osmotic minipumps in the cerebella of the
Ptch1+/−/Tis21−/− mice, a mouse model that we have
previously generated, which develops Shh-dependent MBs
at high frequency (80%) (Farioli-Vecchioli et al., 2012).
The treatment lasted 4 weeks and started in 1-month-old
Ptch1+/−/Tis21−/− mice, i.e., at a stage when MB lesions,
generated by pGCPs, have already started to form and represent
MB at its initial expansion (Kim et al., 2003; Farioli-Vecchioli
et al., 2012). The lesions were identified by visualizing the
proliferating pGCPs as BrdU+ cells, 1 h after an injection of
BrdU (Figures 1A,B). As shown in Figures 1C–E and in Table 1,
we observed that in 2-month-old Ptch1+/−/Tis21−/− mice,
previously treated with Cxcl3 for 28 days, the percentage of mice
presenting cerebellar lesions was 0.0%, whereas it was 62.5% in
CSF-treated mice (p = 0.007 Chi square test; n = 8 mice treated
with Cxcl3 and n = 8 mice treated with CSF). Correspondingly,
the average number of MB lesions per cerebellum resulted
0.0 ± 0.0 in Cxcl3-treated and 0.62 ± 0.1 in vehicle-treated mice
(p = 0.0042 Student’s t-test). Thus, the chronic infusion of the
chemokine Cxcl3 into the cerebellum of the high frequency MB
mouse model Ptch1+/−/Tis21−/− prevents and/or suppresses
the development of MB lesions.
As a next step, we sought to define whether this striking anti-
lesion effect was dependent on the duration of Cxcl3 application.
We analyzed the frequency of MB lesions by treating 1-month-
old Ptch1+/−/Tis21−/− mice for a shorter period (14 days) with
the same Alzet minipumps filled with recombinant Cxcl3 or
with CSF (Figure 2A). At this time no significant differences
were detected between Cxcl3-treated and CSF-treated mice in
the percentage of MB lesions or in the number of lesions per
cerebellum (see Table 1), indicating that 2 weeks of Cxcl3
treatment are not sufficient to counteract the development of the
MB lesions.
Thus, we reasoned that the absence of lesions in mice
treated for a month with Cxcl3 could depend on the protracted
period of forced migration out of the lesion of the pGCPs
induced by the chemokine. Then, to verify the effect of Cxcl3
on pGCPs migration and differentiation, we analyzed the
percentage of pGCPs migrated outside lesions in 6-week-old
Ptch1+/−/Tis21−/− mice previously treated with Cxcl3 or CSF
for 14 days, labeled with one injection of BrdU 5 days before
analysis, and following their migration to the ML and IGL
(Figures 2A–C). pGCPs were double labeled (BrdU+NeuN+) to
monitor also their differentiation (Figures 2D,E); in fact NeuN
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FIGURE 1 | Administration of Cxcl3 for 28 days suppresses the development of MB lesions. (A) Scheme of minipump implant and (B) treatment timeline:
1-month-old Ptch1+/−/Tis21−/− mice were treated for 4 weeks with Alzet minipumps filled with recombinant Cxcl3 or with CSF alone; a single BrdU injection was
performed 1 h before analysis. (C,D) Representative images of cerebellar sagittal sections from 2-month-old Ptch1+/−/Tis21−/− mice treated with CSF (C) or Cxcl3
(D), with or without an MB lesion, respectively. Nuclei were stained with Hoechst 33258 and lesions were identified by the presence of BrdU+ pGCPs (red). Scale
bar, 300 µm. (E) Higher magnification of the preneoplastic lesion indicated in (C) (white box). Scale bar, 100 µm.
marks post-mitotic, terminally differentiated, cerebellar granule
neurons (Weyer and Schilling, 2003). In Cxcl3-treated mice
we observed an evident increase in the percentage of BrdU+
pGCPs migrated from the lesion to the ML and IGL (about 80%
and fourfold, respectively), relative to control mice (percentage
of BrdU+/total BrdU+ in Cxcl3-treated vs. CSF-treated mice,
p= 0.0013 in ML and p= 0.00008 in IGL; Figures 2B,C). Almost
all of the BrdU+ pGCPs migrated to the ML and IGL resulted
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FIGURE 2 | Cxcl3 delivered in vivo in the cerebellum has a strong pro-migratory effect on pGCPs. (A) Scheme of treatment: 1-month-old
Ptch1+/−/Tis21−/− mice were treated for 14 days with Alzet minipumps filled with recombinant Cxcl3 or with CSF alone; mice received a single BrdU injection at
P39 and were analyzed 5 days after (P44). (B) Representative confocal images of pGCPs migrating outside the lesions, identified at 6 weeks of age as BrdU+ cells
(red) in the Ptch1+/−/Tis21−/− mice treated with CSF or Cxcl3. Sections are counterstained with Hoechst 33258 to visualize the ML and the IGL. Scale bar, 50 µm.
L: lesion. (C) The pGCPs migrating from lesions were quantified as mean ± SEM percentage ratio of BrdU+ cells present within the ML or the IGL area neighboring
each lesion to the total number of BrdU+ cells in lesion, ML and IGL. All lesions present in each mouse cerebellum were analyzed. CSF n = 3 lesions (seven mice),
Cxcl3 n = 2 lesions (seven mice). ∗∗p < 0.01, ∗∗∗p < 0.001, Student’s t-test. (D) The same confocal sections of (B) are shown with pGCPs double labeled for
BrdU+NeuN+ (red and green, respectively) and counterstained with Hoechst 33258 to visualize the ML and the IGL. Scale bar, 50 µm. White arrows indicate some
of the BrdU+NeuN+ cells. (E) Quantification of the differentiated pGCPs [shown in graph (C) as BrdU+], analyzed as mean ± SEM percentage ratio of BrdU+NeuN+
cells present within the ML or the IGL area neighboring each lesion to the total number of BrdU+ cells in lesion, ML and IGL. CSF n = 3 lesions (seven mice), Cxcl3
n = 2 lesions (seven mice). ∗∗p < 0.01, ∗∗∗p < 0.001, Student’s t-test.
terminally differentiated (85 and 90%, respectively; percentage of
BrdU+NeuN+/total BrdU+ cells in Cxcl3-treated vs. CSF-treated
mice, p= 0.002 in ML and p= 0.00008 in IGL; Figures 2D,E).
We conclude that Cxcl3 delivered in vivo in the cerebellum
exerts a powerful pro-migratory effect on pGCPs – continuously
forcing them to leave lesions – accompanied by a pro-
differentiative effect resulting from the exit of pGCPs out of the
mitogenic area at the cerebellar surface.
DISCUSSION
Current cancer therapies target proliferation and survival of
tumor cells, mainly using toxic chemicals. Instead, in this study
we tested the feasibility to reduce the frequency of MB lesions by
forcing the preneoplastic granule neuron precursor cells (pGCPs)
to migrate out of the lesions at the surface of the cerebellum and
differentiate, withdrawing from the tumor program, by means of
an intracerebellar treatment with the chemokine Cxcl3.
Some chemokines have been shown to be expressed in
cerebellum, such as Cxcl2 (Rossi and Zlotnik, 2000), or Cxcl12
and Cxcl3, which inhibit (Ma et al., 1998) or promote (Farioli-
Vecchioli et al., 2012), respectively, the migration of the GCPs
out of the EGL.
Moreover, we have recently shown by real time-PCR and by
in situ analysis that the chemokine Cxcl3 is expressed in normal
as well as in preneoplastic GCPs in MB lesions and also in
granule neurons in the IGL; furthermore, we have ascertained
the expression of the Cxcl3 receptor (CXCR2) in GCPs (Farioli-
Vecchioli et al., 2012).
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To increase the levels of Cxcl3 in vivo in the pGCPs
of the high frequency MB mouse model Ptch1+/−/Tis21−/−,
we treated chronically 1-month-old mice with Cxcl3 in
cerebellum by implantation of Alzet osmotic minipumps. As
a result, after 1 month of intracerebellar administration of the
chemokine, the tumor lesions disappeared or were prevented
completely. Since the tumor lesions present at 2 months of
age in Ptch1+/−/Tis21−/− mice develop invariably into a MB
(Farioli-Vecchioli et al., 2012), these data represent a proof
of concept that the treatment with Cxcl3 can reduce MB
formation. This suggests that the timing chosen to start the
treatment, i.e., when the lesions have already started to develop
(1 month after birth), is appropriate. Nevertheless, since a
shorter treatment does not attain a significant reduction of
lesion number, this study also suggests that the reduction of
the frequency of MB lesions is dependent on the duration
of Cxcl3 application. The observed delay in Cxcl3 effect on
lesion frequency after 14 days of treatment may depend on the
time required for diffusion and influence of Cxcl3 on brain
microenvironment. In fact, in isolated cerebellar slices from
MB Ptch1+/−/Tis21−/− mice we observed a rapid decrease of
the area of MB lesions within 5 days (Farioli-Vecchioli et al.,
2012).
Notably, we showed in this report that the absence of lesions
in the mice treated with Cxcl3 was correlated with increased
migration out of the lesion and with differentiation of the pGCPs
following the exposure to the chemokine. In fact, in mice treated
with Cxcl3 for 2 weeks we observed a significant increase in
the percentage of differentiated pGCPs (BrdU+NeuN+) migrated
out of the lesion to the ML and IGL, relative to control mice.
Interestingly, the percentage of BrdU+ pGCPs migrated out the
lesion to either the ML or IGL of CSF-treated Ptch1+/−/Tis21−/−
mice matched the values of the pGCPs migration previously
observed without minipumps (Farioli-Vecchioli et al., 2012), thus
ruling out a possible effect of the CSF treatment on the ability of
pGCPs to migrate out of lesions.
As a whole, our data confirm the importance of the
timing of migration of GCPs in the MB pathogenesis and
demonstrate, for the first time, the possibility to prevent or
fully inhibit MB development by the migration-promoting
action of Cxcl3. This chemokine, mimicking the morphogenetic
migration process of GCPs from EGL to IGL, forces the pGCPs
to differentiate and exit the neoplastic program, instead of
controlling their proliferation. Moreover, it is worth mentioning
that Cxcl3 is devoid of any intrinsic action on the differentiation
or proliferation of the GCPs (Farioli-Vecchioli et al., 2012).
Interestingly, a recent report showed that Cxcl3 promotes the
proliferation and tumorigenesis of hepatocarcinoma cancer stem
cells (Zhang et al., 2016). This, however, it not surprising,
as it is quite common to have cell-specific effects among
chemokines, including Cxcl3, and also considering that GCPs,
although of epithelial origin as epatic cells, are not stem
cells. As an example of different cell specificities, Cxcl3 has
different actions on endothelial-derived blood cells, since it
promotes the arrest of monocytes (Smith et al., 2005), while
acts as chemoattractant for neutrophils to areas of brain injury
(Szmydynger-Chodobska et al., 2009). Thus, different pathways
are likely to be involved. In this regard, a recent analysis of
genomic pathways in the Ptch1+/−/Tis21−/− mouse model
suggests that the chemotaxis mechanism of the GCPs by the
Cxcl3-Cxcr2 axis may be clathrin-dependent (Gentile et al.,
2016).
Further studies will be necessary to assess whether Cxcl3
will efficiently reduce the frequency of MBs also starting at
later stages of MB development (after 1 month of age). And
it will also be necessary to test whether the induction of
migration at later stages could be less beneficial because of an
increasing refractoriness of the pGCPs to leave the neoplastic
program and differentiate, thus increasing the possibility of
metastases.
If Cxcl3 will be validated as a therapeutic agent also at later
stages of tumorigenesis, this will improve the possibility to use the
chemokine in human therapy. Moreover, given that the control
of migration of neural precursors is operative also in other neural
tumors, this potential therapy may have wider application.
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